| Literature DB >> 27690075 |
Huixiao Hong1, Diego Rua2, Sugunadevi Sakkiah3, Chandrabose Selvaraj4, Weigong Ge5, Weida Tong6.
Abstract
Sunscreen products are predominantly regulated as over-the-counter (OTC) drugs by the US FDA. The "active" ingredients function as ultraviolet filters. Once a sunscreen product is generally recognized as safe and effective (GRASE) via an OTC drug review process, new formulations using these ingredients do not require FDA review and approval, however, the majority of ingredients have never been tested to uncover any potential endocrine activity and their ability to interact with the estrogen receptor (ER) is unknown, despite the fact that this is a very extensively studied target related to endocrine activity. Consequently, we have developed an in silico model to prioritize single ingredient estrogen receptor activity for use when actual animal data are inadequate, equivocal, or absent. It relies on consensus modeling to qualitatively and quantitatively predict ER binding activity. As proof of concept, the model was applied to ingredients commonly used in sunscreen products worldwide and a few reference chemicals. Of the 32 chemicals with unknown ER binding activity that were evaluated, seven were predicted to be active estrogenic compounds. Five of the seven were confirmed by the published data. Further experimental data is needed to confirm the other two predictions.Entities:
Keywords: estrogenic activity; ingredient; model; prediction; sunscreen
Year: 2016 PMID: 27690075 PMCID: PMC5086697 DOI: 10.3390/ijerph13100958
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Figure 1Structures of the 38 ingredients selected for this work. The numbers under structures were used in the text and Tables. The compounds shown in panel (A) were used in UV and non-UV filers; The compounds given in panel (B) are the benzophenone derivatives (potential excipients in sunscreen products and cosmetics).
Figure 2Workflow of the consensus classification modeling for classifying sunscreen ingredients as ER binders and non-binders.
Figure 3Workflow of the consensus regression modeling for estimating ER binding affinity of sunscreen ingredients.
Estrogenic activity of sunscreen ingredients.
| Compounds, UV Filters | Qualitative Prediction * | Quantitative Prediction ** | |||
|---|---|---|---|---|---|
| ID | CAS | OTC Drug Name/ | +/− | Conf | |
| 1 | 150-13-0 | Aminobenzoic acid/ | + | (26) | logRA10 = −3.523 |
| 2 | 118-60-5 | Octisale/ | − | (30) | |
| 3 | 131-57-7 | Oxybenzone/ | − | (5) | |
| 4 | 131-53-3 | Dioxybenzone/ | − | (5,27) | |
| 5 | 21245-02-3 | Padimate/ | − | (27) | |
| 6 | 4065-45-6 | Sulisobenzone/ | + | 0.310 | −2.915 |
| 7 | 38102-62-4 | + | 0.102 | −1.431 | |
| 8 | 2174-16-5 | Trolamine salicylate/ | − | 0.794 | |
| 9 | 27503-81-7 | Ensulizole/ | − | 0.034 | |
| 10 | 70356-09-1 | Avobenzone/ | − | 0.601 | |
| 11 | 104-28-9 | Cinoxate/ | − | 0.654 | |
| 12 | 134-09-8 | Meradimate/ | − | 0.581 | |
| 13 | 5466-77-3 | Octinoxate/ | − | 0.597 | |
| 14 | 6197-30-4 | Octocrylene/ | − | 0.157 | |
| 15 | 71617-10-2 | − | 0.654 | ||
| 16 | 155633-54-8 | − | 0.077 | ||
| 17 | 103597-45-1 | − | 0.191 | ||
| 18 | 118-56-9 | Homosalate/ | − | 0.206 | |
| 19 | 13463-67-7 | Titanium dioxide/ | − | 0.694 | |
| 20 | 1314-13-2 | Zinc oxide/ | − | 0.795 | |
| 21 | 154702-15-5 | − | 0.756 | ||
| 22 | 88122-99-0 | − | 0.756 | ||
| 23 | 187393-00-6 | − | 0.012 | ||
| 24 | 92761-26-7 | Ecamsule/ | − | 0.072 | |
| 25 | 3380-34-5 | Triclosan/ | + | (28) | logRBA = −3.280 |
| 26 | 190085-41-7 | + | 0.827 | −0.853 | |
| 27 | 65277-42-1 | Ketoconazole | − | 0.046 | |
* Prediction confidence is a number between 0 and 1 for indication of confidence for a prediction: the smaller the number, the less confident the prediction. ** Prediction is in log10(RBA). RBA is the relative binding affinity to the natural estrogen, estradiol. RBA of estradiol is set to 100 and, thus, its log10(RBA) = 2. INCI = International Nomenclature of Cosmetic Ingredients. INCI names are used in the United States, the European Union, Japan and many other countries for listing ingredients on sunscreen product labels.
Predicted Estrogenic activity of benzophenone derivatives.
| Compounds, Benzophenone Derivative | Qualitative Prediction * | Quantitative Prediction ** | |||
|---|---|---|---|---|---|
| ID | CAS | Name/ | +/− | Conf | |
| 3 | 131-57-7 | Oxybenzone/ | − | (5) | |
| 4 | 131-53-3 | Dioxybenzone/ | − | (5,27) | |
| 6 | 4065-45-6 | Sulisobenzone/ | + | 0.310 | −2.915 |
| 28 | 131-56-6 | 2,4-dihydroxybenzophenone/ | + | 0.875 | −2.710 |
| 29 | 131-55-5 | 2,2′,4,4′-Tetrahydroxybenzophenone/ | + | 0.900 | −1.609 |
| 30 | 6628-37-1 | Sulisobenzone sodium/ | + | 0.600 | −2.614 |
| 31 | 85-19-8 | 5-Chloro-2-hydroxybenzophenone/ | + | 0.777 | −2.778 |
| 32 | 131-54-4 | 2,2′-Dihydroxy-4,4′-dimethoxybenzophenone/ | − | 0.100 | |
| 33 | 76656-36-5 | Sodium 2,2′-dihydroxy-4,4′-dimethoxybenzophenone-5,5′-disulfonate/ | − | 0.300 | |
| 34 | 1641-17-4 | Mexenone, 2-hydroxy-4-methoxy-4′-methylbenzophenone/ | − | 0.100 | |
| 35 | 1341-54-4 | − | 0.100 | ||
| 36 | 1843-05-6 | Octabenzone/ | − | 0.140 | |
| 37 | 954-16-5 | Trimethylbenzophenone | − | 0.997 | |
| 38 | 119-61-9 | Benzophenone | − | 0.996 | |
* Prediction confidence is a number between 0 and 1 for indication of confidence for a prediction: the smaller the number, the less confident the prediction. ** Prediction is in log10(RBA). RBA is the relative binding affinity to the natural estrogen, estradiol. RBA of estradiol is set to 100 and, thus, its log10(RBA) = 2. INCI = International Nomenclature of Cosmetic Ingredients. INCI names are used in the United States, the European Union, Japan and many other countries for listing ingredients on sunscreen product labels.
Figure 4Classification performance of the 5-fold cross validations. Classification accuracy (blue), sensitivity (red), specificity (magenta), MCC (cyan) and balanced accuracy (black) of the 1000 iterations of 5-fold cross validations were plotted for TS-1 (A) and TS-2 (B). Parameter values were indicated at the x-axis and the y-axis represents the frequency of cross validations.
Cross validation results.
| Parameter | Result (Mean ± Std) | |
|---|---|---|
| TS-1 | TS-2 | |
| Accuracy | 0.816 (±0.018) | 0.801 (±0.009) |
| Sensitivity | 0.859 (±0.020) | 0.640 (±0.018) |
| Specificity | 0.761 (±0.031) | 0.877 (±0.010) |
| MCC | 0.625 (±0.037) | 0.533 (±0.021) |
| Balanced Accuracy | 0.810 (±0.019) | 0.758 (±0.010) |
Std: standard deviation; MCC: Mathews correlation coefficient.
Figure 5Regression performance of the 5-fold cross validations. The distributions of Q values were plotted as blue and red lines for TS-3 and TS-4 (A). The average predicted logRBA of the 1000 iterations of 5-fold cross validations were plotted against the actual logRBA for TS-3 (B) and TS-4 (C).
Figure 6External validation results. The x-axis indicates actual logRBA values and the y-axis gives the estimated logRBA values from model M-3 that was developed using TS-3.